Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent or Metastatic Urethral Cancer
Local recurrences of urethral cancer may be amenable to local modality therapy with radiation or surgery, with or without chemotherapy. (Refer to the Treatment Option Overview section of this summary for more information.) Metastatic disease may be treated with regimens in common use for other urothelial transitional cell or squamous cell carcinomas, or anal carcinomas, depending upon the histology.[1,2,3]Treatment options:Locally recurrent urethral cancer after radiation therapy should be treated by surgical excision, if feasible.Locally recurrent urethral cancer after surgery alone should be considered for combination radiation and wider surgical resection.Metastatic urethral cancer should be considered for clinical trials using chemotherapy. Transitional cell cancer of the urethra may respond favorably to the same chemotherapy regimens employed for advanced transitional cell cancer of the bladder.[2,3,4,5]The level of evidence for these treatment options is 3iiiDiv.Current Clinical
Bladder and Other Urothelial Cancers Screening (PDQ®): Screening - Health Professional Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Bladder and Other Urothelial Cancers Screening (PDQ®): Screening - Health Professional Information [NCI] - Overview
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about Bladder and Other Urothelial Cancers screening.
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IV Bladder Cancer Treatment
Currently, only a small fraction of patients with stage IV bladder cancer can be cured and for many patients, the emphasis is on palliation of symptoms. The potential for cure is restricted to patients with stage IV disease with involvement of pelvic organs by direct extension or metastases to regional lymph nodes.Standard Treatment Options for Stage IV Bladder CancerStandard treatment options for patients with T4b, N0, M0 or any T, N1–N3, M0 diseaseTreatment options for patients with T4b, N0, M0 or any T, N1–N3, M0 disease include the following:Chemotherapy alone.Radical cystectomy.Radical cystectomy followed by chemotherapy.Radical cystectomy alone.External-beam radiation therapy (EBRT) with or without concomitant chemotherapy.Urinary diversion or cystectomy for palliation.Chemotherapy aloneCisplatin-based combination chemotherapy regimens are the standard of care for stage IV bladder cancer.[2,3,4,5,6] The only chemotherapy regimens that have been
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Bladder Cancer
Related Summaries Note: Other PDQ summaries containing information related to bladder cancer include the following: Bladder and Other Urothelial Cancers Screening Unusual Cancers of Childhood Statistics Note: Estimated new cases and deaths from bladder cancer in the United States in 2010:[ 1 ] New cases: 70,530. Deaths: 14,680. Prognosis Approximately 70% to 80% of patients with newly diagnosed ...
Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options by Stage
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Stage 0 (Papillary Carcinoma and Carcinoma in Situ)Treatment of stage 0 may include the following:Transurethral resection with fulguration.Transurethral resection with fulguration followed by intravesical biologic therapy or chemotherapy.Segmental cystectomy.Radical cystectomy.A clinical trial of photodynamic therapy.A clinical trial of biologic therapy.A clinical trial of chemoprevention therapy given after treatment so the condition will not recur (come back).Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage 0 bladder cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Bladder and Other Urothelial Cancers Screening (PDQ®): Screening - Health Professional Information [NCI] - Changes to This Summary (08 / 08 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of EvidenceAdded text to state that a positive family history of bladder cancer has also been associated with an increased risk of bladder cancer (cited Burger et al. as reference 3).Added Gu et al., Engel et al., and Sanderson et al. as references 8, 10, and 14, respectively.Revised text to state that a variety of industrial exposures have also been implicated as risk factors for developing bladder cancer, primarily aromatic amines, such as 2-naphthylamine, beta-naphthylamine, or 4-chloro-o-toluidine, present in the production of dyes and benzidine and its derivatives; possibly chlorinated aliphatic hydrocarbons; chlorination by-products in treated water; aluminum production (polycyclic aromatic hydrocarbons, fluorides), and certain aldehydes.Revised text to state that
Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for Bladder Cancer
Nonmuscle-invasive Bladder CancerTreatment of nonmuscle-invasive bladder cancers (Ta, Tis, T1) is based on risk stratification. Essentially all patients are initially treated with a transurethral resection (TUR) of the bladder tumor followed by a single immediate instillation of intravesical chemotherapy (mitomycin C is typically used in the United States).[1,2,3,4,5,6,7]Subsequent therapy after the treatment above is based on risk and typically consists of one of the following:[6,7,8,9]Surveillance for relapse or recurrence (typically used for tumors with low risk of recurrence or progression).A minimum of 1 year of intravesical treatments with bascillus Calmette-Guérin (BCG) plus surveillance for relapse (typically used for tumors at intermediate or high risk of progression to muscle-invasive disease).Additional intravesical chemotherapy (typically used for tumors with a high risk of recurrence but low risk of progression to muscle-invasive disease).Muscle-invasive
Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (10 / 05 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. This summary was comprehensively reviewed and extensively revised.This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.